Introduction
============

We recently reported a 728-patient multicenter study (Sapphire) where a biomarker combination of tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7) were validated for risk stratification for moderate or severe acute kidney injury (AKI) KDIGO stage 2 and 3 \[[@B1]\].

Methods
=======

We subsequently selected two clinical cutoff values for the TIMP2 × IGFBP7 combination from the Sapphire dataset, one (0.3) with high sensitivity (89%) (specificity = 50%) and one (2.0) with high specificity (95%) (sensitivity = 42%) for the development of AKI KDIGO stage 2 and 3 within 12 hours of study enrolment. We examined the timing of change in TIMP2 × IGFBP7 relative to change in creatinine using the sign test.

Results
=======

TIMP2 × IGFBP7 results were available for 178 patients who developed AKI stage 2 or 3. The median TIMP2 × IGFBP7 result was significantly greater than the cutoff value of 0.3 from 24 hours before to 24 hours after AKI 2 or 3 (*P*\< 0.01) (Figure [1](#F1){ref-type="fig"}). Conversely, median serum creatinine was not different from baseline prior to development of AKI 2 or 3.

![**NC, Nephrocheck (TIMP2 × IGFBP7); Cr, creatinine**.](cc13570-1){#F1}

Conclusion
==========

The TIMP2 × IGFBP7 biomarker combination identifies patients who ultimately develop moderate or severe AKI 24 hours earlier than serum creatinine.
